valvular disease (9 men, 7 women) or at an autopsy (within 3 h postmortem) from AF patients who had died of chronic heart failure (2 men), and from patients with neither underlying heart nor thromboembolic diseases but who had chronic AF (2 men). The clinical data of all AF patients are shown in Table 1 . Before heart surgery, an echocardiograph and cardiac catheter examination were routinely performed. Although most operative patients had one or more episodes of congestive heart failure (New York Heart Association functional class III-IV), cardiac catheter examination and heart surgery were performed under well-controlled conditions with digoxin (13 of 16 cases) and diuretic (12 of 16 cases) treatment. Two patients with mitral valvular disease had a history of cerebral infarction, which was confirmed by a computed tomographic scan of the head. For antithrombotic therapy, a full-dose of warfarin and/or a lowdose of aspirin were administered in 13 of 20 AF patients examined. For comparison with data from non-AF patients, we used the same atrial appendage specimens that had previously been used (3 with mitral valvular disease, 6 with aortic valvular disease, 6 with ischemic heart disease, 2 with chronic heart failure, and 6 with non-cardiac patients; 13 men/10 women). 13 The average age was similar for AF and non-AF patients examined (64±13 vs 62±10 years, NS).
Immunohistochemistry
Atrial tissue was immediately fixed in 4% paraformaldehyde for 6 h at room temperature. Three millimeter sections were cut from the tissue block and were frozen in liquid N2. Serial cryostat sections (4 m thick) were cut from each tissue block and were immunostained by using the avidinbiotin -immunoperoxidase method. 19 Briefly, sections were incubated serially with the following solutions: (i) 2% hydrogen peroxide for 30 min; (ii) 0.3% Triton X-100 for 15 min; (iii) 10% normal goat serum for 60 min; (iv) primary antisera for 16 h at 4°C; (v) biotinylated goat anti-mouse or goat anti-rabbit IgG at a dilution of 1:200 for 45 min; and (iv) avidin-biotinylated horseradish peroxidase complex (Vectastain, Vector Laboratories, Burlingame, California, USA) at a dilution of 1:100 for 45 min. Immunoreactive sites were visualized by incubation with 0.025% 3,3-diaminobenzidine and 0.01% hydrogen peroxide for 3 min. Phosphate buffered saline (PBS, pH 7.4) was used to dilute each solution and to wash the sections three times between each step. Finally, tissue sections were counterstained with hematoxylin.
As primary antisera, polyclonal anti-vWF antibodies (Dako, Glostrup, Denmark) were used to evaluate immunoreactive vWF in the endocardium. To confirm the integrity of the endothelium, serial sections were also immunostained for another endothelial cell marker, CD31 (Dako). Platelet adhesion/aggregation was detected by using a monoclonal antibody against glycoprotein Ib/IX (GP Ib/IX) (PharMingen, San Diego, California, USA). Fibrinogen and/or fibrin deposition was detected by using 2 monoclonal antibodies; 1 that selectively reacts with fibrin alone (Immunotech, Marseille, France) and another that reacts with both fibrinogen and fibrin (fibrinogen/fibrin; Oxford Biotechnology Ltd, Kidlington, UK). The specificity of immunostaining was assessed by incubation with nonimmunized rabbit or mouse serum instead of the primary antiserum.
In Situ Hybridization
Digoxigenin-labeled cRNA probes for in situ hybridization were prepared according to the manufacturer's instructions (Boehringer Mannheim, Mannheim, Germany). Antisense and sense probes were generated from pBluescript II plasmid (Stratagene, LA Jolla, California, USA) containing the 2,334-2,816 site of human vWF cDNA 20 T7 RNA polymerase, respectively. In situ hybridization was performed by using a digoxigenin system. 19 
Histologic Analysis
Immunohistochemistry and in situ hybridization for vWF were assessed by light microscopic observation. Consistent with a previous report, the endothelium of most intramyocardial vessels showed apparent vWF staining in all atrial appendages examined (Fig 1B vs F) . 13 Thus, the staining intensity in the endocardium was semiquantitatively graded in comparison with the endothelium of intramyocardial vessels of the same sections (grade 1, only focal or little staining; grade 2, diffuse, weaker staining; grade 3, similar staining; and grade 4, stronger staining). The 
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grading was performed independently by 2 observers who had no prior knowledge of the case histories. For cases in which a discrepancy between the 2 observers was found, the final score was determined by joint observation. As an index of structural remodeling in the myocardium, the mean myocyte diameter was obtained as the average of 100-200 myocytes in each atrial appendage. [4] [5] [6] To minimize the influence of tissue sectioning, the myocyte diameter in the shortest axis including the nucleus, was measured. The degree of platelet adhesion/aggregation in the endocardium was graded as previously described according to the GP Ib/IX staining in each atrial tissue section (grade 1, no adhesion; grade 2, a few patchy adhesions; grade 3, multiple and/or widespread adhesions; and grade 4, thrombi containing other blood cell types). 13 
Statistical Analysis
Continuous variables were expressed as mean ± SD and were compared between the 2 groups by using a paired or unpaired Student's t-test. The relationship between the immunohistochemical and in situ hybridization grades for vWF in the endocardium and the relationship between the immunohistochemical grade for vWF and continuous variables were examined by using Spearman's rank correlation. A plot of the relationship between the immunohistochemical grade for vWF in the endocardium and mean myocyte diameter in the myocardium was compared between different patient groups by covariance of ANOVA. The percentage of positive staining for vWF, fibrinogen/fibrin, and fibrin associated with the grade of platelet adhesion/aggregation on the endocardium was compared by chi-squared analysis. Values of p<0.05 were considered to be significant.
Results
In any operative and autopsy tissue specimens, immunoreactivity for CD31 in the endothelial cells was preserved in most areas of the endocardial surface as well as in the intramyocardial vessels (Fig 1A,E) . In AF patients with mitral valvular disease, immunoreactivity for vWF in the endocardium was, in general, weaker in the right atrial appendages (RAA) compared with that in the left atrial appendages (LAA) (Fig 1B) . For in situ hybridization of vWF in the LAA, but not in RAA, strong signals were found in the overlying endothelium (Fig 1C) . Negative control sections incubated with the sense probe showed no specific staining (Fig 1D) . Table 1 summarizes the data. It is noted that strong vWF staining in the endocardium (grade 3 to 4) was seen in all LAA of AF patients with either mitral stenosis or mitral regurgitation, whereas variable vWF staining (grade 1 to 3) was seen among the RAA of the same patients. In AF patients who had died of chronic heart failure, strong vWF staining in the endocardium (grade 3 to 4) was seen in both RAA and LAA (Table 1 ). In contrast, only focal or weak vWF staining in the endocardium (grade 1 to 2) was seen in both RAA and LAA of patients with AF alone (Fig 1E,F) . The endothelium of most intramyocardial vessels showed apparent vWF staining in autopsy tissues as well as in the operative tissues (Fig 1B vs F) . A plot of the relationship between the immunohistochemical and in situ hybridization grades for vWF in the endocardium showed a significant correlation (r=0.86, p<0.001 by Spearman's rank correlation; Fig 1G) .
Echocardiography showed enlarged left atrial dimensions in all AF patients with mitral valvular disease (54± 8.1 mm). In association with this atrial enlargement, the myocyte diameters in the LAA were increased when compared with those of patients with AF alone (Fig 2A vs B , 23±2.6 m vs 15±1.7 m; p<0.01). To examine the effects of AF and structural remodeling on the endocardial expression of vWF, we plotted the relationship between the immunohistochemical grade for vWF in the endocardium and mean myocyte diameter in the underlying myocardium (Fig 2C) . However, as most LAA had the highest vWF grade and increased myocyte diameters (closed triangles), LAA specimens were not suitable for statistical analysis. A significant correlation between the 2 variables was present for the data of RAA for which the vWF grade had a wide variation (closed circles; p<0.01 by Spearman's rank correlation). A similar correlation was found for the data of RAA specimens obtained from non-AF patients (open circles, p<0.01). There was no significant difference in the plot of RAA data between the AF and non-AF patient groups (NS by covariance of ANOVA). A variety of vWF grades in the endocardium of RAA was not correlated with any clinical and hemodynamic variables including age, sex, cardiac index, and pulmonary capillary wedge pressure or with any medications before heart surgery.
Thrombus formation on the endocardium was found in 5 of 14 LAA and 8 of 18 RAA from AF patients who had underlying heart disease, but not in any atrial specimens from patients with AF alone. Thin layers of platelet adhesion/aggregation positive to GP Ib/IX staining were always accompanied by strong, extensive vWF staining and focal or weak fibrinogen/fibrin staining in the endocardium (Fig 3A-C) . No selective fibrin staining was seen in most sites with thin platelet adhesion layers (Fig 3D) and also in any sections without platelet adhesion/aggregation. In small thrombi that extruded into the lumen, platelet adhesion/aggregation was found on the endocardium and was associated with apparent staining for vWF, fibrinogen/fibrin, and fibrin (Fig 3E-H) . However, it is noted that platelet adhesion/aggregation was colocalized with strong vWF staining, but not necessarily with fibrinogen and/or fibrin staining (Fig 3E vs G and H) . In some patients who had had an episode of stroke, macroscopic thrombi that adhered to the endocardial surface of LAA was observed (Fig 3I) . Under the fresh thrombi, platelet adhesion/aggregation was found immediately adjacent to the endocardial surface and was associated with the staining for vWF and fibrin (Fig 3J-L) . Most other areas of the fresh thrombi were occupied by red blood cell aggregates (Fig 3I). Fig 4 summarizes the positive staining for vWF, fibrinogen/fibrin, and fibrin associated with the grade of platelet adhesion/aggregation on the endocardium.
Discussion
In AF patients, the expression of vWF in the endocardium was widely varied among the individual atrial appendages examined. The increased expression of vWF in the endocardium was associated with an enlarged atrial dimension or increased myocyte size in the underlying myocardium. Platelet GP Ib/IX staining was found on the adherent endocardial surface of the fresh thrombi and was colocalized with strong vWF staining, but not necessarily with fibrinogen and/or fibrin staining. These results suggest that the expression of vWF in the atrial endocardium may be increased in association with structural remodeling contributing to intra-atrial thrombogenesis in AF via platelet adhesion/aggregation on the endocardium.
Variable Expression of vWF in the Atrial Endocardium
The present study provides direct evidence that the immunoreactive and mRNA signals for vWF in the endocardium are well correlated and vary widely among atrial appendages of AF patients with and without underlying heart diseases. In all cases examined, the integrity of the endocardial endothelium was confirmed by the preserved staining for another endothelial cell marker, CD31. As vWF synthesized in the endothelium is secreted into the subendothelium as well as into the lumen, it is most likely that variable immunoreactivity for vWF in the endocardium reflects its synthetic activity in the overlying endothelial cells. 14 In contrast, it has been reported that the plasma levels of vWF are elevated in patients with mitral stenosis 21 or chronic AF. 22 Goldsmith et al have shown that the plasma levels of vWF in such patients are correlated with the extent of endothelial cell damage in the endocardium. 7 Although it is unclear whether high plasma levels of vWF reflect endothelial activation or endothelial dysfunction, 23 our results suggest there is increased synthesis of vWF in the left atrial endocardium of AF patients with mitral valvular disease.
vWF Expression and Atrial Fibrillation
It is evident that the presence of AF itself is not necessarily associated with increased expression of vWF in the atrial endocardium. First, only focal or weak vWF staining in the endocardium was seen in both RAA and LAA of patients with AF alone (Fig 1F) , as had been observed in non-cardiac patients. 13 In addition, in patients with mitral valvular disease, the expression of vWF in the endocardium differed markedly between the RAA and LAA, which were both involved in AF (Fig 1; Table 1 ). It is also noteworthy that strong expression of vWF in the endocardium of LAA was seen irrespective of whether mitral valve lesion was stenotic or regurgitant. These observations suggest that alterations in the flow pattern or amplitude in the atrial cavity may not be important in regulating the vWF expression in the atrial endocardium, 16, 17 which is consistent with an experimental study that used cultured endothelial cells. 24 In the present study, we demonstrated an intimate association between the expression of vWF in the endocardium and the mean myocyte diameter in the underlying myocardium (Fig 2C, closed symbols) . A similar correlation was also found in the plot for non-AF patients (Fig 2C, open  circles) . Hypertrophic changes in the atrial myocytes have been shown to be a non-specific finding seen in both AF and non-AF cardiac patients. 25 Therefore, it is conceivable that the variable expression of vWF in the endocardium is more directly associated with mechanical stress in the atrial wall than with AF itself. This may explain the strong vWF expression in the RAA of AF patients who had died of chronic heart failure compared with those of AF patients in whom heart failure had been well controlled before heart surgery ( Table 1) . Although mechanical stress may directly modulate the expression of vWF in the endocardium, it is also possible that the resultant remodeling myocardium may influence the vWF expression in the overlying endocardium. Edelberg et al have shown that vWF expression in cardiac microvascular endothelial cells is regulated by myocyte-induced platelet-derived growth factor production in those cells. 26 Further studies are required to clarify the precise mechanism underlying the variable expression of vWF in the endocardium.
Differential Roles of vWF and Fibrinogen/Fibrin in Intra-Atrial Thrombogenesis
Platelet adhesion/aggregation on the endocardial surface was found in all stages of intra-atrial thrombi, as shown in Fig 3. Although it is known that vWF plays an essential role in platelet adhesion, especially at high shear rates, 27 our observations suggest that this molecule is inevitably involved in platelet adhesion/aggregation on the endocardium (Figs 3,4) . Subendothelial vWF derived from the overlying endothelium is bound to type VI collagen rather than types I and III collagen, which are located deeper in the subendothelium. 15 In addition, platelet adhesion to type VI collagen has been shown to occur only at low shear rates (100-300 /s) whereas platelet adhesion to types I and III collagen occurs at higher shear rates. [28] [29] [30] [31] Therefore, when vWF is immobilized to type VI collagen, vWF-mediated platelet adhesion is likely to occur even in the low shear rate conditions. 29 Indeed, it has been reported that subendothelial vWF and subsequent platelet attachment contribute to increased thrombogenicity of the vein compared with the artery. 32 Platelet adhesion at a low shear rate has been also shown to occur on fibrinogen-or fibrin-coated surfaces. 33 In the present study, focal or weak fibrinogen/fibrin staining, but little selective fibrin staining, was seen in sites with thin platelet adhesion layers on the endocardium (Fig 3A-D; 4) . Strong fibrinogen and/or fibrin staining was seen in the thrombi that extruded into the lumen, but was not necessarily colocalized with platelet adhesion/aggregation (Fig 3E-L) . Our observations may be consistent with the report by Matsui et al in which fibrinogen and/or fibrin are mainly involved in thrombus growth rather than initial platelet adhesion to the thrombogenic surfaces. 34 
Conclusions
In the present study, we demonstrated that the expression of vWF mRNA and protein in the endocardium was variable among the atrial appendages of AF patients, correlating with the extent of structural remodeling in the atrial wall. Subendothelial vWF compared with fibrinogen and/or fibrin appeared to be important especially in platelet adhesion/aggregation on the endocardium, which was found in all stages of intra-atrial thrombi. Based on these results, we suggest that apart from rheologic factors in AF, the increased expression of vWF in the atrial endocardium may contribute to the thrombotic predilection of AF associated with structural remodeling.
